Skip to main content

Advertisement

Table 5 Multivariate analyses of associations between clinical characteristics and SF-36 scores of mRCC patients

From: Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma

Variable PF score RP score BP score GH score VT score SF score RE score MH score
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Sex (man vs. woman) 1.611 (0.786–3.302) 0.193 1.419 (0.692–2.909) 0.339 0.737 (0.337–1.613) 0.446 0.884 (0.421–1.885) 0.744 0.861 (0.428–1.730) 0.674 0.955 (0.476–1.917) 0.898 1.673 (0.796–3.513) 0.174 0.850 (0.423–1.710) 0.649
Age (<65 vs. ≥65 years) 0.689 (0.347–1.402) 0.312 0.821 (0.401–1.680) 0.589 0.721 (0.329–1.580) 0.414 0.794 (0.378–1.665) 0.541 1.636 (0.802–3.337) 0.176 0.814 (0.406–1.632) 0.562 1.033 (0.506–2.109) 0.929 1.310 (0.61–2.636) 0.449
MSKCC grade (favorable vs. others) 1.184 (0.441–3.179 0.738 2.557 (0.905–7.339) 0.076 1.089 (0.371–3.195) 0.877 1.927 (0.721–5.153) 0.191 0.887 (0.334–2.357) 0.811 1.939 (0.714–5.265) 0.194 1.128 (0.413–3.085) 0.814 0.804 (0.305–2.122) 0.660
IMDC risk (good vs. others) 0.689 (0.347–1.402) 0.713 0.202 (0.041–1.003) 0.050 0.465 (0.371–3.195) 0.399 0.665 (0.157–2.809) 0.579 0.454 (0.109–1.887) 0.277 0.527 (0.129–2.157) 0.373 1.077 (0.258–4.499) 0.919 1.529 (0.383–6.104) 0.548
AE grade (1–2 vs. 3–4) 0.699 (0.268–1.828) 0.465 3.711 (1.263–10.910) 0.017 4.259 (1.561–11.622) 0.005 1.411 (0.532–3.747) 0.489 0.758 (0.289–1.989) 0.573 1.718 (0.641–4.603) 0.282 2.035 (0.695–5.960) 0.329 2.465 (0.889–6.835) 0.083
Treatment (sorafenib vs. sunitinib) 1.141 (0.620–2.099) 0.671 1.001 (0.539–1.859) 0.998 1.335 (0.694–2.568) 0.387 0.595 (0.311–1.139 0.117 0.735 (0.401–1.348) 0.320 1.033 (0.564–1.890) 0.917 1.364 (0.731–2.545) 0.721 1.340 (0.730–3.462) 0.345
  1. PF physical functioning, RP role-physical, BP bodily pain, GH general health, VT vitality, SF social functioning, RE role-emotional, MH mental health, IMDC International Metastatic Renal Cell Carcinoma Database Consortium